Key result
Argatroban concentration-dependently inhibited clot-induced platelet aggregation (IC50 21 nM) and TXB2 release (IC50 13 nM), demonstrating superiority of direct thrombin inhibitors over heparin.
Why the study?
Does argatroban inhibit platelet aggregation induced by clot-associated thrombin more effectively than heparin or hirudin in an in vitro model?
Does argatroban inhibit platelet aggregation induced by clot-associated thrombin more effectively than heparin or hirudin in an in vitro model?
Direct-acting thrombin inhibitors like argatroban are superior to heparin in inhibiting platelet activation by clot-associated thrombin, providing a mechanistic basis for their use in platelet-rich thrombi.
No takes yet. Share an insight, caveat, or question.
May support direct thrombin inhibitors in platelet-rich thrombi; leaves open clinical translation from animal data.
Lunven et al. (1996) studied this question. Argatroban vs. Recombinant hirudin and Heparin was evaluated on Inhibition of clot-induced platelet aggregation and TXB2 release. Argatroban concentration-dependently inhibited clot-induced platelet aggregation (IC50 21 nM) and TXB2 release (IC50 13 nM), demonstrating superiority of direct thrombin inhibitors over heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: